Date 11:00 AM EDT | May 22, 2025
Register for Creative Biolabs’ Webinar
The relentless pursuit of innovative cancer immunotherapies has unveiled natural killer (NK) cells as formidable agents in the fight against malignancies. While these innate immune cells possess inherent tumor-killing capabilities, their full potential remains constrained by regulatory mechanisms and tumor evasion strategies. At the forefront of this research stands ADAM17, a membrane-associated protease that functions as both a negative regulatory checkpoint in NK cells and a tumor-associated antigen overexpressed in various malignancies. Creative Biolabs is honored to invite Dr. Bruce Walcheck to introduce the Targeted ADAM17 Blocker and Killer (TABK), an ingenious multi-engager antibody complex that simultaneously enhances NK cell proliferation while directing these empowered immune cells to engage and eliminate ADAM17-expressing tumor cells. Join us to explore how this innovative approach leverages ADAM17’s unique dual role to create a potent immunotherapeutic strategy with promising implications for cancer treatment.
During this webinar, we will discuss the following key points:
NK cell-mediated natural cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC)
Utilizing NK cells to kill cancer cells
ADAM17, a membrane-associated protease expressed by NK cells
ADAM17 functions as a negative regulatory checkpoint in NK cells and is a tumor-associated antigen
ADAM17 inhibition by the mAb Medi-1 enhances NK cells activation and proliferation
Development of the multi-engager antibody complex Targeted ADAM17 Blocker and Killer (TABK)
TABK selectively blocks ADAM17 in NK cells and synergizes with IL-15 stimulation to enhance NK cell activation and proliferation
TABK engages ADAM17 overexpressed by various malignancies, linking NK cells to tumor cells to mediate their killing
